...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents.
【24h】

Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents.

机译：缬沙坦对裸金属支架经皮冠状动脉介入治疗后靶病变血运重建的有益作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Angiotensin II receptor blockers (ARB) have been shown to reduce cardiovascular events in patients at risk. The effect of valsartan on outcomes after percutaneous coronary interventions (PCI) with bare-metal stents (BMS) was investigated. METHODS AND RESULTS: The prospective, randomized study included 191 patients at 5 participating institutions, who were randomly assigned to either a 40-80 mg valsartan add-on or non-ARB treatment. The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, and target lesion revascularization (TLR) at 18 months. Enrollment was stopped when the use of drug-eluting stents has been expanded in Japan. No significant differences existed between the groups in terms of primary endpoint (18.9% vs. 24.8%; hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.61-1.14; P = 0.26). In the valsartan group, as compared with the non-ARB group, the secondary endpoint of TLR was significantly reduced at a median follow-up 4.4 years; the rate of TLR was from 27.8% to 14.5% (HR, 0.69; 95%CI, 0.49-0.96; P = 0.024). CONCLUSIONS: Valsartan treatment was not superior to non-ARB treatment in reducing the primary endpoint after PCI at 18 months. The pre-specified secondary endpoint of TLR was lower in the valsartan group, but this needs to be proved statistically with an adequate study sampling.
机译：背景：血管紧张素II受体阻滞剂（ARB）已显示可减少高危患者的心血管事件。研究了缬沙坦对裸金属支架（BMS）的经皮冠状动脉介入治疗（PCI）后预后的影响。方法和结果：前瞻性随机研究包括5个参与机构的191例患者，这些患者被随机分配接受40-80 mg缬沙坦附加或非ARB治疗。主要终点是18个月时全因死亡，非致命性心肌梗塞和目标病变血运重建（TLR）的综合结果。日本扩大了药物洗脱支架的使用后，停止了注册。在主要终点方面，两组之间无显着差异（18.9％对24.8％;危险比[HR]为0.84; 95％置信区间[CI]为0.61-1.14; P = 0.26）。与非ARB组相比，在缬沙坦组中，TLR的次要终点在中位随访4.4年时显着降低。 TLR率为27.8％至14.5％（HR，0.69; 95％CI，0.49-0.96; P = 0.024）。结论：缬沙坦治疗在减少PCI 18个月后的主要终点方面并不优于非ARB治疗。在缬沙坦组中，TLR的预先设定的次要终点较低，但这需要通过足够的研究样本进行统计证明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号